| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015745939 |
| P356 | DOI | 10.1186/1472-6750-11-126 |
| P932 | PMC publication ID | 3295704 |
| P698 | PubMed publication ID | 22185669 |
| P5875 | ResearchGate publication ID | 51903758 |
| P50 | author | Lennart Hammarström | Q5786999 |
| Beatriz Alvarez | Q75230431 | ||
| Kasper Krogh Andersen | Q125221679 | ||
| P2093 | author name string | Prosper N Boyaka | |
| Harold Marcotte | |||
| P2860 | cites work | Significant differences between Lactobacillus casei subsp. casei ATCC 393T and a commonly used plasmid-cured derivative revealed by a polyphasic study. | Q45315512 |
| A single-dose combination therapy that both prevents and treats anthrax infection. | Q46032501 | ||
| Expression of single-chain antibody against RgpA protease of Porphyromonas gingivalis in Lactobacillus | Q46906804 | ||
| The aggregation-promoting factor of Lactobacillus crispatus M247 and its genetic locus. | Q51618303 | ||
| Effects of unpaired cysteines on yield, solubility and activity of different recombinant antibody constructs expressed in E. coli | Q58008250 | ||
| In situ delivery of passive immunity by lactobacilli producing single-chain antibodies | Q74381949 | ||
| Construction of compatible wide-host-range shuttle vectors for lactic acid bacteria and Escherichia coli | Q74600969 | ||
| Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea | Q79327324 | ||
| Being prepared: modeling the response to an anthrax attack | Q81662763 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Crystal Structure of the Engineered Neutralizing Antibody M18 Complexed to Domain 4 of the Anthrax Protective Antigen | Q27654632 | ||
| Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells | Q28243539 | ||
| A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars | Q28245353 | ||
| Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor | Q28269030 | ||
| Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain | Q28302768 | ||
| Anthrax toxin: the long and winding road that leads to the kill | Q28304927 | ||
| Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells | Q28609196 | ||
| Anthrax as a biological weapon, 2002: updated recommendations for management | Q29615587 | ||
| Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax | Q30233063 | ||
| Stability engineering of antibody single-chain Fv fragments | Q30978689 | ||
| Primary involvement of pharynx and peyer's patch in inhalational and intestinal anthrax | Q33286415 | ||
| The commensal microbiology of the gastrointestinal tract | Q33374575 | ||
| Stability engineering of scFvs for the development of bispecific and multivalent antibodies | Q33574335 | ||
| Receptors of anthrax toxin and cell entry. | Q34659076 | ||
| Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice | Q35085358 | ||
| Japanese Biological Warfare Research on Humans: A Case Study of Microbiology and Ethics | Q35218197 | ||
| Gastrointestinal anthrax: review of the literature | Q35580710 | ||
| Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice | Q35679008 | ||
| Interactions between anthrax toxin receptors and protective antigen | Q36032399 | ||
| Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. | Q36997570 | ||
| Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge | Q37110110 | ||
| Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria | Q37111626 | ||
| Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells | Q37374866 | ||
| Identification and characterization of the novel LysM domain-containing surface protein Sep from Lactobacillus fermentum BR11 and its use as a peptide fusion partner in Lactobacillus and Lactococcus. | Q40937780 | ||
| Integrative expression system for delivery of antibody fragments by lactobacilli. | Q42706463 | ||
| Anthrax vaccine: short-term safety experience in humans | Q43819297 | ||
| Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity | Q44013452 | ||
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 126 | |
| P577 | publication date | 2011-12-20 | |
| P1433 | published in | BMC Biotechnology | Q15753225 |
| P1476 | title | In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli | |
| P478 | volume | 11 |
| Q26740788 | An update on antibody-based immunotherapies for Clostridium difficile infection |
| Q38132268 | Anthrax vaccines: present status and future prospects. |
| Q35159650 | Co-expression of anti-rotavirus proteins (llama VHH antibody fragments) in Lactobacillus: development and functionality of vectors containing two expression cassettes in tandem |
| Q26753101 | Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications |
| Q42252027 | Engineered Lactobacillus rhamnosus GG expressing IgG-binding domains of protein G: Capture of hyperimmune bovine colostrum antibodies and protection against diarrhea in a mouse pup rotavirus infection model |
| Q37346068 | Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus. |
| Q40641101 | Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus |
| Q38827869 | Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option |
| Q26786083 | Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes |
| Q42697422 | Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies |
| Q39120553 | Optimizing antibody expression: The nuts and bolts |
| Q36127715 | Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats |
| Q35544342 | Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT |
Search more.